Tradename: ALTUVIIIO

Proper Name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl

Indication: Indicated for use in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding.                              

Approval Date: 02/22/2023

Manufacturer: Bioverativ Therapeutics, Inc.